Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae

Infection, Genetics and Evolution

Volumn 11, Issue 7, 2011, Pages 1499-1504

  Chong, Yong ^a   Ito, Yoshikiyo ^a   Kamimura, Tomohiko ^a  

^a HARASANSHIN HOSPITAL   (Japan)

Author keywords

Antibiotic resistance; ESBL; Escherichia coli; Genetic evolution; Klebsiella pneumoniae

Indexed keywords

BETA LACTAMASE; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M 15; BETA LACTAMASE SHV; BETA LACTAMASE TEM 1; BETA LACTAMASE TEM 2; CARBAPENEM; CEPHALOSPORIN; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; COMMUNICABLE DISEASE; CTX M 15 GENE; CTX M GENE; DRUG MISUSE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE GENE; GENE INSERTION SEQUENCE; GENETIC EPIDEMIOLOGY; GENETIC VARIABILITY; GRAM NEGATIVE SEPSIS; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INTEGRON; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MOLECULAR CLONING; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; QUINOLONE RESISTANCE GENE; REVIEW; SHV GENE; TEM GENE; TRANSPOSON; URINARY TRACT INFECTION;

BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; EVOLUTION, MOLECULAR; GENES, BACTERIAL; HUMANS; INTERSPERSED REPETITIVE SEQUENCES; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

EID: 80053572626     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2011.06.001     Document Type: Review

References (65)

1. Babini G.S., Livermore D.M. Are SHV beta-lactamases universal in Klebsiella pneumoniae?. Antimicrob Agents Chemother. 2000, 44:2230.
2. Baraniak A., Fiett J., Sulikowska A., Hryniewicz W., Gniadkowski M. Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob. Agents Chemother. 2002, 46:151-159.
3. Bauernfeind A., Grimm H., Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 1990, 18:294-298.
4. Ben-Ami R., Schwaber M.J., Navon-Venezia S., Schwartz D., Giladi M., Chmelnitsky I., et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin. Infect. Dis. 2006, 42:925-934.
5. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother 2004, 48:1-14.
6. Boyd D.A., Tyler S., Christianson S., McGeer A., Muller M.P., Willey B.M., et al. Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Antimicrob. Agents Chemother. 2004, 48:3758-3764.
7. Branger C., Zamfir O., Geoffroy S., Laurans G., Arlet G., Thien H.V., et al. Genetic background of Escherichia coli and extended-spectrum beta-lactamase type. Emerg. Infect. Dis. 2005, 11:54-61.
8. Brun-Buisson C., Legrand P., Philippon A., Montravers F., Ansquer M., Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987, 2:302-306.
9. Bush K. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol. 2010, 13:558-564.
10. Canton R., Coque T.M. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol. 2006, 9:466-475.
11. Canton R., Novais A., Valverde A., Machado E., Peixe L., Baquero F., et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2008, 14(Suppl. 1):144-153.
12. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob. Agents Chemother. 2009, 53:2227-2238.
13. Carattoli A., Lovari S., Franco A., Cordaro G., Di Matteo P., Battisti A. Extended-spectrum beta-lactamases in Escherichia coli isolated from dogs and cats in Rome, Italy, from 2001 to 2003. Antimicrob. Agents Chemother. 2005, 49:833-835.
14. Chong Y., Yakushiji H., Ito Y., Kamimura T. Cefepime-resistant Gram-negative bacteremia in febrile neutropenic patients with hematological malignancies. Int. J. Infect. Dis. 2010, 14(Suppl 3):e171-e175.
15. Chong Y., Yakushiji H., Ito Y., Kamimura T. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a long-term study from Japan. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30:83-87.
16. Deschamps C., Clermont O., Hipeaux M.C., Arlet G., Denamur E., Branger C. Multiple acquisitions of CTX-M plasmids in the rare D2 genotype of Escherichia coli provide evidence for convergent evolution. Microbiology 2009, 155:1656-1668.
17. Diestra K., Juan C., Curiao T., Moya B., Miro E., Oteo J., et al. Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of Escherichia coli and Klebsiella pneumoniae. J. Antimicrob. Chemother. 2009, 63:60-66.
18. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect. Dis. 2010, 10:43-50.
19. Gudiol C., Calatayud L., Garcia-Vidal C., Lora-Tamayo J., Cisnal M., Duarte R., et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J. Antimicrob. Chemother. 2010, 65:333-341.
20. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E., Hsueh P.R., Paterson D.L. Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob. Agents Chemother. 2009, 53:3280-3284.
21. Jacoby G.A., Munoz-Price L.S. The new beta-lactamases. N. Engl. J. Med. 2005, 352:380-391.
22. Johnson J.R., Johnston B., Clabots C., Kuskowski M.A., Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 2010, 51:286-294.
23. Karim A., Poirel L., Nagarajan S., Nordmann P. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol. Lett. 2001, 201:237-241.
24. Kelesidis T., Karageorgopoulos D.E., Kelesidis I., Falagas M.E. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 2008, 62:895-904.
25. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11:315-317.
26. Kojima A., Ishii Y., Ishihara K., Esaki H., Asai T., Oda C., et al. Extended-spectrum-beta-lactamase-producing Escherichia coli strains isolated from farm animals from 1999 to 2002: report from the Japanese Veterinary Antimicrobial Resistance Monitoring Program. Antimicrob. Agents Chemother. 2005, 49:3533-3537.
27. Lavollay M., Mamlouk K., Frank T., Akpabie A., Burghoffer B., Ben Redjeb S., et al. Clonal dissemination of a CTX-M-15 beta-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob. Agents Chemother. 2006, 50:2433-2438.
28. Lewis J.S., Herrera M., Wickes B., Patterson J.E., Jorgensen J.H. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 2007, 51:4015-4021.
29. Livermore D.M. Beta-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 1995, 8:557-584.
30. Marcade G., Deschamps C., Boyd A., Gautier V., Picard B., Branger C., et al. Replicon typing of plasmids in Escherichia coli producing extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 2009, 63:67-71.
31. Mnif B., Vimont S., Boyd A., Bourit E., Picard B., Branger C., et al. Molecular characterization of addiction systems of plasmids encoding extended-spectrum beta-lactamases in Escherichia coli. J. Antimicrob. Chemother. 2010, 65:1599-1603.
32. Morosini M.I., Garcia-Castillo M., Coque T.M., Valverde A., Novais A., Loza E., et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 2006, 50:2695-2699.
33. Muratani T., Kobayashi T., Matsumoto T. Emergence and prevalence of beta-lactamase-producing Klebsiella pneumoniae resistant to cephems in Japan. Int. J. Antimicrob. Agents 2006, 27:491-499.
34. Nicolas-Chanoine M.H., Blanco J., Leflon-Guibout V., Demarty R., Alonso M.P., Canica M.M., et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. 2008, 61:273-281.
35. Novais A., Canton R., Valverde A., Machado E., Galan J.C., Peixe L., et al. Dissemination and persistence of blaCTX-M-9 are linked to class 1 integrons containing CR1 associated with defective transposon derivatives from Tn402 located in early antibiotic resistance plasmids of IncHI2, IncP1-alpha, and IncFI groups. Antimicrob. Agents Chemother. 2006, 50:2741-2750.
36. Oteo J., Orden B., Bautista V., Cuevas O., Arroyo M., Martinez-Ruiz R., et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J. Antimicrob. Chemother. 2009, 64:712-717.
37. Oteo J., Perez-Vazquez M., Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr. Opin. Infect. Dis. 2010, 23:320-326.
38. Palucha A., Mikiewicz B., Hryniewicz W., Gniadkowski M. Concurrent outbreaks of extended-spectrum beta-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J. Antimicrob. Chemother. 1999, 44:489-499.
39. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 2005, 18:657-686.
40. Peirano G., Pitout J.D. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 2010, 35:316-321.
41. Peirano G., Costello M., Pitout J.D. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int. J. Antimicrob. Agents 2010, 36:19-23.
42. Philippon A., Labia R., Jacoby G. Extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 1989, 33:1131-1136.
43. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 2008, 8:159-166.
44. Pitout J.D., Gregson D.B., Campbell L., Laupland K.B. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. Antimicrob. Agents Chemother. 2009, 53:2846-2851.
45. Poirel L., Lartigue M.F., Decousser J.W., Nordmann P. ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob. Agents Chemother. 2005, 49:447-450.
46. Poirel L., Naas T., Nordmann P. Genetic support of extended-spectrum beta-lactamases. Clin. Microbiol. Infect. 2008, 14(Suppl 1):75-81.
47. Poirel L., Al Maskari Z., Al Rashdi F., Bernabeu S., Nordmann P. NDM-1-producing Klebsiella pneumoniae isolated in the Sultanate of Oman. J. Antimicrob. Chemother. 2010, 66:304-306.
48. Poirel L., Lagrutta E., Taylor P., Pham J., Nordmann P. Emergence of metallo-beta-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia. Antimicrob. Agents Chemother. 2010, 54:4914-4916.
49. Poirel L., Revathi G., Bernabeu S., Nordmann P. Detection of NDM-1-producing Klebsiella pneumoniae in Kenya. Antimicrob. Agents Chemother. 2011, 55:934-936.
50. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother. 2007, 60:1018-1029.
51. Rodriguez-Bano J., Navarro M.D., Romero L., Muniain M.A., de Cueto M., Rios M.J., et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 2006, 43:1407-1414.
52. Rodriguez-Bano J., Lopez-Cerero L., Navarro M.D., Diaz de Alba P., Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J. Antimicrob. Chemother. 2008, 62:1142-1149.
53. Rodriguez-Bano J., Alcala J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 2008, 168:1897-1902.
54. Rodriguez-Bano J., Picon E., Gijon P., Hernandez J.R., Ruiz M., Pena C., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis. 2010, 50:40-48.
55. Rossolini G.M., D'Andrea M.M., Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin. Microbiol. Infect. 2008, 14(Suppl. 1):33-41.
56. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2007, 60:913-920.
57. Sidjabat H.E., Paterson D.L., Adams-Haduch J.M., Ewan L., Pasculle A.W., Muto C.A., et al. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob. Agents Chemother. 2009, 53:4733-4739.
58. Suzuki S., Shibata N., Yamane K., Wachino J., Ito K., Arakawa Y. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J. Antimicrob. Chemother. 2009, 63:72-79.
59. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 42:657-668.
60. Toleman M.A., Bennett P.M., Walsh T.R. ISCR elements: novel gene-capturing systems of the 21st century?. Microbiol. Mol. Biol. Rev. 2006, 70:296-316.
61. Valverde A., Coque T.M., Sanchez-Moreno M.P., Rollan A., Baquero F., Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J. Clin. Microbiol. 2004, 42:4769-4775.
62. Valverde A., Coque T.M., Garcia-San Miguel L., Baquero F., Canton R. Complex molecular epidemiology of extended-spectrum beta-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid. J. Antimicrob. Chemother. 2008, 61:64-72.
63. Vigil K.J., Johnson J.R., Johnston B.D., Kontoyiannis D.P., Mulanovich V.E., Raad I.I., et al. Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin. Infect. Dis. 2010, 50:374-380.
64. Woerther P.L., Angebault C., Lescat M., Ruppe E., Skurnik D., Mniai A.E., et al. Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population. J. Infect. Dis. 2010, 202:515-523.
65. Yuan M., Aucken H., Hall L.M., Pitt T.L., Livermore D.M. Epidemiological typing of klebsiellae with extended-spectrum beta-lactamases from European intensive care units. J. Antimicrob. Chemother. 1998, 41:527-539.